Kevin Fitzgerald

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi request reprint RNAi versus small molecules: different mechanisms and specificities can lead to different outcomes
    Kevin Fitzgerald
    Bristol Myers Squibb Co, Department of Applied Genomics, Pharmaceutical Research Institute, P O Box 5400, Princeton, NJ 08534, USA
    Curr Opin Drug Discov Devel 8:557-66. 2005
  2. ncbi request reprint Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors
    Mark R Lackner
    Exelixis Inc, 170 Harbor Way, South San Francisco, California 94083, USA
    Cancer Cell 7:325-36. 2005
  3. pmc Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
    Maria Frank-Kamenetsky
    Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, USA
    Proc Natl Acad Sci U S A 105:11915-20. 2008

Collaborators

  • Muthiah Manoharan
  • Jürgen Soutschek
  • Petra Ross-Macdonald
  • Maria Frank-Kamenetsky
  • Mark R Lackner
  • Tracy Zimmermann
  • Ingo Röhl
  • K Narayanannair Jayaprakash
  • Hans Peter Vornlocher
  • Timothy Read
  • Antonin de Fougerolles
  • Jamie Wong
  • Jay D Horton
  • Aldo Grefhorst
  • Yupeng Fan
  • Victor Koteliansky
  • Akin Akinc
  • Robert Langer
  • Lubomir Nechev
  • Robert Dorkin
  • Pamela Tan
  • Gang Wang
  • Matthias John
  • Kallanthottathil G Rajeev
  • Philipp Hadwiger
  • Christina Gamba-Vitalo
  • David Butler
  • Martin Maier
  • Daniel G Anderson
  • Muthusamy Jayaraman
  • Birgit Bramlage
  • Klaus Charisse
  • Timothy S Racie
  • Norma N Anderson
  • Pamela M Carroll
  • Heshani de Silva
  • Tak Hung
  • Tim Heuer
  • Rajashekar K Reddy
  • Hangjun Zhan
  • Kevin Keegan
  • Carol O'Brien
  • Michael R Cancilla
  • Michael Costa
  • Rachel M Kindt
  • Yvonne Franke
  • Dianne Parry
  • Mark Cockett
  • Hong Xiao
  • Juan J Perez-Villar
  • Bo Guan
  • Jae Moon Lee
  • Changyou Chen
  • Veeraswamy Manne
  • Katherine Brown
  • Greg Plowman

Detail Information

Publications3

  1. ncbi request reprint RNAi versus small molecules: different mechanisms and specificities can lead to different outcomes
    Kevin Fitzgerald
    Bristol Myers Squibb Co, Department of Applied Genomics, Pharmaceutical Research Institute, P O Box 5400, Princeton, NJ 08534, USA
    Curr Opin Drug Discov Devel 8:557-66. 2005
    ..This review discusses the similarities, as well as the predicted differences between RNAi and small molecule effects on therapeutic paradigms and drug discovery...
  2. ncbi request reprint Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors
    Mark R Lackner
    Exelixis Inc, 170 Harbor Way, South San Francisco, California 94083, USA
    Cancer Cell 7:325-36. 2005
    ..These findings validate RabGGT, and by extension endosomal function, as a therapeutically relevant target for modulation of apoptosis, and enhance our understanding of the mechanism of action of FTIs...
  3. pmc Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
    Maria Frank-Kamenetsky
    Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, USA
    Proc Natl Acad Sci U S A 105:11915-20. 2008
    ..These results validate PCSK9 targeting with RNAi therapeutics as an approach to specifically lower LDLc, paving the way for the development of PCSK9-lowering agents as a future strategy for treatment of hypercholesterolemia...